Iovance Biotherapeutics Inc

Latest Results (10.10.2025):

Iovance Biotherapeutics Inc reported its financial results for the second quarter of 2025, demonstrating robust growth in product revenue and implementing strategic initiatives to enhance its financial stability and market presence.

Total Product Revenue Growth

In the second quarter of 2025, Iovance Biotherapeutics Inc achieved a total product revenue of $60.0 million, marking a 93% year-over-year increase from $31.1 million in Q2 2024. This growth was driven primarily by strong sales of Amtagvi® and Proleukin.

Amtagvi® Sales and Patient Reach

Amtagvi® generated $54.1 million in product revenue during Q2 2025, with over 100 patients treated. The increase in infusion volumes was fueled by expanded activities in existing Authorized Treatment Centers (ATCs) and the onboarding of new ATCs, facilitating broader patient access.

Proleukin Revenue Insights

Proleukin sales contributed $5.9 million to the total product revenue in Q2 2025. This rise reflects restocking orders from major U.S. wholesalers in response to the growing utilization of Amtagvi®. Iovance anticipates continued growth in Proleukin revenue in the latter half of 2025.

Full Year 2025 Revenue Guidance

Iovance Biotherapeutics Inc reiterated its full-year 2025 total product revenue guidance of $250 million to $300 million. The forecast aligns with anticipated growth in ATCs, increased Proleukin sales, and expanding market access in both existing and new regions.

Strategic Restructuring and Financial Stability

The company is undergoing a strategic restructuring aimed at optimizing business performance, which is expected to generate over $100 million in annual cost savings starting in Q4 2025. This initiative extends Iovance’s cash runway into the fourth quarter of 2026, ensuring sustained operational stability.

Expansion of Authorized Treatment Centers

Iovance has expanded its Amtagvi® treatment network to over 80 U.S. ATCs across 35 states, ensuring that 95% of addressable patients are within 200 miles of a center. Ongoing efforts to onboard new ATCs and enhance community referral activities are driving earlier treatment adoption.